Absolute benefit in risk reduction needed to use...
How much absolute benefit in terms of reduction in the risk of relapse do you believe is necessary to justify using a fluoropyrimidine alone (without the inclusion of oxaliplatin)?
How much absolute benefit in terms of reduction in the risk of relapse do you believe is necessary to justify using an oxaliplatin regimen (in addition to fluoropyrimidine)?
 |
Steven R Alberts, MD, MPH |
| Chair, Division of Medical Oncology Professor of Oncology Mayo Clinic Rochester, Minnesota |
I believe that a 5% absolute reduction in the risk of relapse is sufficient for me to initiate treatment with a fluoropyrimidine alone.
Because of the potential side effects of oxaliplatin, I would like to see at least a 5% absolute benefit in relapse risk.
 |
Al B Benson III, MD |
| Professor of Medicine Associate Director for Clinical Investigations Robert H Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois |
In order to initiate treatment with a fluoropyrimidine alone I would like to see an approximately 5% absolute reduction from baseline relapse risk without treatment.
At least a 5% absolute reduction in relapse risk would be necessary for me to use an oxaliplatin-based regimen.
 |
Charles S Fuchs, MD, MPH |
| Director Center for Gastrointestinal Cancer Dana-Farber/Harvard Cancer Center Professor of Medicine Harvard Medical School Boston, Massachusetts |
A 3% absolute benefit in risk of relapse would be necessary for me to begin treatment with a fluoropyrimidine.
I would say 3% to 4% in an absolute setting would be enough to justify adding oxaliplatin to a fluoropyrimidine-based regimen.
 |
Richard M Goldberg, MD |
| Professor of Medicine Physician-in-Chief, OSUCCC - James Cancer Hospital and Richard J Solove Research Institute Klotz Family Chair in Cancer Research The Ohio State University Columbus, Ohio |
A 3% absolute benefit in the reduction of the risk of relapse would be sufficient to initiate treatment if the patient felt that that amount of benefit was worthwhile.
I believe that determination of the necessary benefit to justify using oxaliplatin would be up to the patient, but for me it would be 3% to 4%.
 |
Axel Grothey, MD |
| Professor of Oncology Department of Medical Oncology Mayo Clinic Rochester, Minnesota |
I would need a 5% to 10% absolute benefit in the risk of relapse to begin treatment with a fluoropyrimidine alone.
A 5% absolute benefit in the relapse risk would justify the addition of oxaliplatin to a fluoropyrimidine for me.
 |
Howard S Hochster, MD |
| Associate Director (Clinical Research) Yale Cancer Center Professor of Medicine Yale School of Medicine New Haven, Connecticut |
I would need a 3% absolute benefit in the risk of relapse to start treatment with a fluoropyrimidine alone.
To start treatment with an oxaliplatin-based regimen, I would like to see a 3% to 4% absolute decrease in the risk of relapse.
 |
Herbert I Hurwitz, MD |
| Associate Professor of Medicine Division of Hematology/Oncology Clinical Director, Phase I Program Co-leader, GI Oncology Program Duke University Medical Center Durham, North Carolina |
I would need approximately a 5% absolute benefit in relapse-free survival to initiate treatment with a fluoropyrimidine alone. These are typically long discussions with the patient regarding what this means to them with regard to relapse-free survival versus overall survival benefit.
I would require a 6% to 10% absolute reduction in relapse risk in order for me to add oxaliplatin to a fluoropyrimidine-based regimen.
 |
Wells A Messersmith, MD |
| Professor and Director GI Medical Oncology Program Co-Leader Developmental Therapeutics Program University of Colorado Cancer Center Aurora, Colorado |
I believe that I would need a greater than 5% absolute reduction in relapse risk to initiate treatment with a fluoropyrimidine.
For me, the minimum value that I would like to see is around a 5% absolute benefit in the risk of relapse in order to add oxaliplatin to a fluoropyrimidine regimen. This is the benefit that was seen in the MOSAIC trial.